Active Ingredient History
Human vasopressin, also called antidiuretic hormone (ADH), arginine vasopressin (AVP) or argipressin, is a hormone synthesized from the AVP gene as a peptide prohormone in neurons in the hypothalamus, and is converted to AVP. It then travels down the axon terminating in the posterior pituitary, and is released from vesicles into the circulation in response to extracellular fluid hypertonicity (hyperosmolality). AVP has two primary functions. First, it increases the amount of solute-free water reabsorbed back into the circulation from the filtrate in the kidney tubules of the nephrons. Second, AVP constricts arterioles, which increases peripheral vascular resistance and raises arterial blood pressure. Wikipedia
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Hypotension (approved 2014)
Acute Kidney Injury (Phase 4)
Acute Lung Injury (Phase 2)
Acute Pain (Phase 1/Phase 2)
Anesthesia, General (Phase 4)
Autism Spectrum Disorder (Phase 2)
Autistic Disorder (Phase 2)
Blood Loss, Surgical (Phase 4)
COVID-19 (Phase 4)
Endotoxemia (Phase 4)
General Surgery (Phase 4)
Healthy Volunteers (Phase 2)
Heart Arrest (Phase 4)
Heart Defects, Congenital (Phase 2/Phase 3)
Heart Diseases (Phase 3)
Heart Ventricles (Phase 2/Phase 3)
Hemorrhage (Phase 4)
Hyperaldosteronism (Phase 2)
Hypertension (Phase 3)
Hypertension, Pulmonary (Phase 2)
Hypotension (Early Phase 1)
Hypovolemia (Phase 2/Phase 3)
Hysterectomy, Vaginal (Phase 4)
Inflammation (Phase 4)
Kidney Diseases (Phase 3)
Kidney Failure, Chronic (Phase 2)
Liver Neoplasms (Phase 4)
Macular Edema (Phase 2)
Myoma (Phase 4)
Out-of-Hospital Cardiac Arrest (Phase 2)
Perfusion (Phase 2/Phase 3)
Physiology (Early Phase 1)
Pleural Effusion (Phase 2/Phase 3)
Post-Cardiac Arrest Syndrome (Phase 3)
Psychology, Social (Early Phase 1)
Pulmonary Arterial Hypertension (Phase 4)
Renal Insufficiency, Chronic (Phase 2)
Respiration, Artificial (Phase 4)
Sepsis (Phase 2/Phase 3)
Shock (Phase 4)
Shock, Hemorrhagic (Phase 2/Phase 3)
Shock, Septic (Phase 4)
Shock, Traumatic (Phase 2)
Uterine Diseases (Phase 3)
Vasoplegia (Phase 3)
Vasopressins (Phase 4)
Wounds and Injuries (Phase 2)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
